Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Condom HPV labeling

This article was originally published in The Tan Sheet

Executive Summary

Reps. Tom Davis (R-Va.) and Mark Souder (R-Ind.) are pressing FDA to fulfill a legislative mandate directing the agency to review condom labeling to ensure information on the products' ability to prevent human papillomavirus (HPV) is "medically accurate." HPV recently was added to federal lists of known cancer-causing agents because certain strains are linked to cervical cancer. Last year, FDA pledged to address HPV and condom labeling by year-end as part of a guidance, but the document has yet to be published, Souder and Davis note in a Feb. 11 letter. The reps request FDA provide within 30 days "a date certain as to when the [agency] will finally be in compliance with Public Law 106-554" and "an explanation for the continued delay by FDA in complying with this four-year-old law." Souder spearheaded a similar effort early last year (1"The Tan Sheet" Jan. 5, 2004, In Brief)...

Related Content

Condoms labeling





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts